Two copies of G2019S Parkinson's gene mutation doesn't lead to more severe diseaseSeptember 12, 2006No observable differences between homozygous and heterzygous state A group of Parkinson's disease researchers concluded there are no observable differences between those who have two copies of the most common mutation of the recently discovered LRRK2 gene and those who have only one copy. Their study will be published in the September edition of the Archives of Neurology. In most diseases with a genetic cause or component, two copies of a bad gene lead to more severe visible manifestation of the disease. Researchers expected to see worse symptoms, the disease start earlier in life and a shorter life span for those with two copies of the LRRK2 gene with the G2019S mutation. "That proved not to be the case," says Mayo Clinic neurologist Zbigniew Wszolek, M.D. Wszolek formed an international consortium that compared the clinical features of Parkinson's disease in the two groups. "It's puzzling," he says. "More studies are needed. More patients need to be identified and, hopefully, more basic science research is going to be performed to find out why." The G2019S mutation is the most common of the 20 identified LRRK2 disease-causing mutations. There are six known genes that cause familial Parkinson's disease, but only one, the G2019S mutation of the LRRK2 gene, has been associated with previously unexplained cases of Parkinson's disease. Wszolek and his colleagues hope that studying the ways in which these genes cause disease, especially the G2019S mutation, will lead to improved treatments and even a cure. "We are all united by the common drive to learn more about this disease, to help the people with this illness and to bring us closer to curative treatments," Wszolek says. "And this may be a step in that direction." By pooling their studies from around the globe, Wszolek and his colleagues found 26 people with the G2019S mutation in both copies of their LRRK2 gene-one inherited from the mother and the other from the father. Interestingly, three patients with the dual mutation exhibited no clinical signs of Parkinson's disease, an indication that the gene has incomplete penetrance. This concept means having the gene mutation alone does not lead to developing severe symptoms or even developing any signs of the disease 100 percent of the time. "One may need some additional factors, either genetic or environmental, which work either to produce the disease or to protect one from developing it," Wszolek says. This latest finding supports the theory many hold that the majority of Parkinson's disease cases may only be explained by the interaction of a number of genes or a genetic and environmental interaction. Wszolek and his colleagues found all patients in their study, whether they had one or two G2019S mutations, had asymmetric onset of symptoms, most often tremor, no male or female preponderance, and both groups had a similar range in the age in which symptoms began. In 2004 Wszolek was one of the researchers who discovered the LRRK2 gene caused parkinsonism. He was also part of the team that discovered the G2019S mutation causes parkinsonism in several North American and European families. That was the first time a genetic cause had been associated with typical, late-onset Parkinson's disease. Mayo Clinic, Jacksonville |
|||||||||||||||||||||
| Related Parkinsons Disease Current Events and Parkinsons Disease News Articles Rutgers Research: Direct Evidence of the Role of Sleep in Memory Formation is Uncovered A Rutgers University, Newark and Collége de France, Paris research team has pinpointed for the first time the mechanism that takes place during sleep that causes learning and memory formation to occur. Higher occurrence of Parkinson's linked to low LDL cholesterol People with low levels of LDL cholesterol are more likely to have Parkinson's disease than people with high LDL levels, according to University of North Carolina at Chapel Hill researchers. Synchronous neuronal firing may underlie Parkinson's disease In a finding that contradicts current theories behind Parkinson's disease, neuroscientists at Duke University Medical Center have discovered in mice that critical nerve cells fire all at the same time and thus overwhelm the brain's ability to control the body's movements. Dopamine imbalances cause sleep disorders in animal models of Parkinson's disease and schizophrenia Neuroscientists at Duke University Medical Center working with genetically engineered mice have found that the brain chemical dopamine plays a critical role in regulating sleep and brain activity associated with dreaming. Researchers announce results of study on genetic variation in Parkinson's disease Researchers at the National Institutes of Health (NIH) have completed one of the first large-scale studies of the role of common genetic variation in Parkinson's disease (PD). Laser probe of a brain pigment's anatomy may offer insight into Parkinson's disease In a finding that may offer clues about Parkinson's disease, a team led by Duke University researchers used a sophisticated laser system to gain evidence that a dark brown pigment that accumulates in people's brains consists of layers of two other pigments commonly found in hair. Government cash injection for University spin-out company's stem cell research A spin-out company from the University of Nottingham has been awarded around £250,000 of Government funding to develop innovative stem cell therapies that could one day provide new treatments for patients suffering from illnesses including Parkinson's disease and stroke. Two minutes of magnetic stimulation can change your brain for an hour A couple of minutes is all it takes to 'knock out' bits of your brain for an hour, according to a new study by a University College London (UCL) team. The team have been working on ways to improve a method known as transcranial magnetic stimulation (TMS) and are now using their adapted version of TMS to investigate possible treatments for stroke patients or those with Parkinson's disease. Gene therapy shows promise in model of Parkinson's disease Scientists at the Ecole Polytechnique Federale de Lausanne (EPFL) in Lausanne, Switzerland, have conducted novel experiments that might one day lead to gene therapy treatment options for patients with Parkinson's disease. In research published this week in the Proceedings of the National Academy of Sciences, the research team, led by EPFL President Patrick Aebischer, found that viral delivery of a gene associated with Parkinson's disease protected neurons from degeneration. Parkinson's disease is a progressive, degenerative neurological disorder in which dopamine-producing neurons in the part of the brain responsible for coordinating muscle movement die or become so damaged that they are no Limitations of Current Evaluation Techniques for the Cost-Effectiveness of Treatments for Parkinson's Disease Parkinson's disease (PD) is one of the most common neurodegenerative disorders. Pharmaceutical and surgical therapies for PD are available and can alleviate the symptoms and complications. Unfortunately, despite these therapies, the disease relentlessly progresses. A new study in the journal Value in Health presents a detailed overview of the current decision-analytic models used to evaluate the cost-effectiveness of therapeutic options in Parkinson's disease. More Parkinsons Disease Current Events and Parkinsons Disease News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||